Schedule 13G ownership disclosure

JASPER THERAPEUTICS INC

Common Stock, par value $0.0001 per share · CUSIP: 471871202

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Soleus Private Equity Fund III, L.P.

    Shares: 200,000.00 · Class: 1.3%

  • Soleus Private Equity GP III, LLC

    Shares: 200,000.00 · Class: 1.3%

  • Soleus PE GP III, LLC

    Shares: 200,000.00 · Class: 1.3%

  • Soleus Capital Master Fund, L.P.

    Shares: 1,294,420.00 · Class: 8.6%

  • Soleus Capital, LLC

    Shares: 1,294,420.00 · Class: 8.6%

  • Soleus Capital Group, LLC

    Shares: 1,294,420.00 · Class: 8.6%

  • Soleus Capital Management, L.P.

    Shares: 1,494,420.00 · Class: 9.96%

  • Soleus GP LLC

    Shares: 1,494,420.00 · Class: 9.96%

  • Guy Levy

    Shares: 1,494,420.00 · Class: 9.96%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-012186
Form type
SCHEDULE 13G/A
Filer
Jasper Therapeutics, Inc.
CIK
CIK 1788028
Filed
Feb 11, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub